|
Campath retrospective...lower-risk MDS
There is a new discussion today in the MDS Beacon regarding a recent small retrospective study by German researchers suggesting that a short course of treatment with the immunosuppressive agent, Campath, may be effective and safe for some patients with lower-risk MDS. 
http://www.mdsbeacon.com/news/2013/0...tic-syndromes/
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|